The legal and safety landscape around peptides, stated plainly.
Of the thirty peptides profiled in this library, five are FDA-approved for at least one indication. The remaining twenty-five are not approved for any use in the United States. That ratio is the most important single fact on this website, and it is usually the first thing peptide marketing obscures.
The RUO designation is legitimate for genuine laboratory reagents. It is not a mechanism for lawfully selling unapproved drugs to consumers, and the FDA has said so directly and repeatedly.
In September 2025 the agency issued more than fifty warning letters to online sellers, telehealth providers and compounders marketing compounded GLP-1 products. On 7 April 2026 it published seven further warning letters, all dated 31 March, all from the Center for Drug Evaluation and Research, all resting on the same reasoning: the sites carried RUO and “not for human consumption” language, and the FDA held that this did not matter, because the product pages themselves described appetite suppression, weight loss and glucose regulation. The cited violations included introducing unapproved new drugs into interstate commerce and misbranding.
Intended use is established by the whole context of how a product is presented — the page copy, the claims, the surrounding material. A disclaimer in the footer does not override the sentence above it. This is why our profiles describe biology and evidence, and never usage.
Peptides sit awkwardly across FDA's compounding framework. BPC-157 illustrates it: placed in 503A Category 2 in September 2023 — substances that may present significant safety risks, barred from compounding — then removed from Category 2 in April 2026 after the nomination was withdrawn, but not placed in Category 1. It is now in neither list: not expressly permitted, not expressly prohibited, still not FDA-approved and with no USP monograph. CJC-1295 and TB-500 followed a similar path. FDA's Pharmacy Compounding Advisory Committee was scheduled to take up BPC-157 again on 23–24 July 2026.
The practical consequence: anything you read about peptide legality, including on this site, has a short shelf life. Check the primary sources.
Unapproved peptides are typically supplied outside any pharmaceutical quality system. Independent testing of grey-market peptides has repeatedly found products that are underdosed, mislabelled, contaminated with bacterial endotoxin, or not the stated compound at all. A peptide can be pharmacologically benign and the vial still be dangerous. Sterility, identity, purity and endotoxin load are not verifiable from a label — and a certificate of analysis supplied by the seller is only as trustworthy as the seller.
Most peptides in this library are prohibited under the WADA code — the growth hormone axis agents under S2, and BPC-157 and TB-500 under S0 (non-approved substances). Athletes subject to testing should treat this library as a reason for caution, not a shopping list.
Speak with a licensed physician. That is not a formality in this field: several peptides here interact meaningfully with glucose regulation, the GH/IGF-1 axis, or melanocortin signalling, and a few have documented serious harms. This site cannot advise you, and will not try.